Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thyroid Neoplasms Clear all
Recruiting Phase 2 Interventional

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

NCT06961084
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Iodine-124, Positron Emission Tomography (PET)/Computerized tomography (CT)
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
13 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Active, not recruiting Phase 1 Interventional

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

NCT01947023
View directory record Official record
Conditions
Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Dabrafenib Mesylate, Echocardiography Test, Lapatinib, Lapatinib Ditosylate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Terminated Phase 1 Interventional

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

NCT06270082
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Interventions
IK-595
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Duarte, California • Orange, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

NCT04589624
View directory record Official record
Conditions
Thyroid Gland Carcinoma
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional Results available

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health

NCT04000880
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Ovary Cancer, Prostate Cancer, Thyroid Cancer, Non-Hodgkin Lymphoma
Interventions
Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health, Diet-Exercise, Exercise-Diet, Combined Diet and Exercise
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed No phase listed Observational

Optional Sub-study to Intraoperative Imaging With ICG Registry

NCT02651246
View directory record Official record
Conditions
Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
Interventions
data collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses

NCT00615537
View directory record Official record
Conditions
Thyroid Nodule, Thyroid Cancer, Thyroid Neoplasms, Nodular Goiter
Interventions
Laser Ablation of Thyroid Nodule
Procedure
Lead sponsor
BioTex, Inc.
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

NCT00358956
View directory record Official record
Conditions
Thyroid Cancer
Interventions
ZD6474 (vandetanib)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Little Rock, Arkansas • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 23, 2026, 5:02 PM EDT
Active, not recruiting Phase 2 Interventional

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

NCT04171622
View directory record Official record
Conditions
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Squamous Cell Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions
Lenvatinib, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Not applicable Interventional

Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System

NCT07287176
View directory record Official record
Conditions
Thyroid Nodule, Thyroid Goiter, Ablation
Interventions
nPulse Vybrance Percutaneous Electrode System
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Sarasota, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions
Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 23, 2026, 5:02 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

NCT03899792
View directory record Official record
Conditions
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin

NCT01182285
View directory record Official record
Conditions
Thyroid Neoplasm
Interventions
Valproic Acid, Liothyronine Sodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Phase 3 Interventional

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

NCT06475989
View directory record Official record
Conditions
Refractory Differentiated Thyroid Gland Carcinoma
Interventions
Biospecimen Collection, Cabozantinib, Computed Tomography, Dabrafenib, Magnetic Resonance Imaging, Questionnaire Administration, Trametinib
Procedure · Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
303
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 219 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Active, not recruiting Phase 1 Interventional

Selumetinib and Olaparib in Solid Tumors

NCT03162627
View directory record Official record
Conditions
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands
Interventions
Selumetinib, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy

NCT05579782
View directory record Official record
Conditions
Postoperative Hypoparathyroidism, Thyroid Disease, Thyroid Neoplasms, Thyroid Cancer
Interventions
NIRAF Detection Technology
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Not applicable Interventional

Improving Care for Rural Patients With Solid Tumors

NCT04916990
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Colon Cancer, Rectum Cancer
Interventions
CARES Intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Not listed Phase 2 Interventional

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

NCT02041260
View directory record Official record
Conditions
Differentiated Thyroid Cancer (DTC), Poorly Differentiated Thyroid Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

NCT02223052
View directory record Official record
Conditions
Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions
CC-486, Vidaza
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 23, 2026, 5:02 PM EDT
Terminated Phase 1 Interventional

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

NCT00002947
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
Interventions
indium In 111 pentetreotide
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 23, 2026, 5:02 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

3-D Super Resolution Ultrasound Microvascular Imaging

NCT04136912
View directory record Official record
Conditions
Breast Cancer, Thyroid Cancer
Interventions
Definity, Acoustic Angiography
Drug · Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Terminated Not applicable Interventional Results available

Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

NCT01974284
View directory record Official record
Conditions
Papillary Thyroid Cancer
Interventions
percutaneous ethanol ablation
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1Phase 2 Interventional

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

NCT04742959
View directory record Official record
Conditions
Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
Interventions
TT-00420, Nab-Paclitaxel
Drug · Combination Product
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Chicago, Illinois • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 23, 2026, 5:02 PM EDT
Completed No phase listed Observational

Thyroid Ultrasound Elasticity (TrUE) Imaging

NCT03307694
View directory record Official record
Conditions
Cancer, Thyroid
Interventions
Ultrasound, Shear wave elasticity imaging, Multi-angle compound shear wave elasticity imaging
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 23, 2026, 5:02 PM EDT